Filing
April 28, 2011
Via Edgarlink and Facsimile
Mr. Jeffrey Riedler
Assistant Director
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Assistant Director
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE: ADVENTRX Pharmaceuticals, Inc.
Registration Statement on Form S-1
Post-effective amendment no. 2
Filed March 10, 2011
File No. 333-160778
Registration Statement on Form S-1
Post-effective amendment no. 2
Filed March 10, 2011
File No. 333-160778
Dear Mr. Riedler:
This letter responds to the comments contained in your letter to ADVENTRX Pharmaceuticals,
Inc. (the Company, we or us), dated March 14, 2011, regarding our post-effective amendment
no. 2 (File No. 333-160778) filed on March 10, 2011 (Post-Effective Amendment No. 2). For your
convenience, we have repeated each of your comments and set forth our response immediately after
each comment. Our responses below should not be interpreted as an admission by us of any deficiency
with respect to Post-Effective Amendment No.2.
Post-effective amendment
General
1. | We note your post-effective amendment consists of a two-page prospectus supplement, the
incorporation by reference of your most recent Form 10-K and Form 8-Ks, and advice to
potential investors that they should read, in conjunction with the aforementioned documents,
ten additional prospectus supplements. Instead of referring to prospectus supplements, please
revise the post-effective amendment to actually provide the information requested by Items
3-10 to the extent the information requested by these items is still applicable and not
already included in the Form 10-K incorporated by reference. |
Mr. Jeffrey Riedler
Securities and Exchange Commission
April 28, 2011
Page 2
Securities and Exchange Commission
April 28, 2011
Page 2
ADVENTRX response: On April 28, 2011, we filed post-effective amendment no. 3 to the
registration statements on Form S-1 (File No. 333-160778 and File No. 333-162361)
(Post-Effective Amendment No. 3). The prospectus supplement included in Post-Effective
Amendment No. 3 does not include reference to or advise potential investors to read
prospectus supplements no. 1 11.
Incorporation by Reference of Certain Documents, page 2
2. | We note your post-effective amendment incorporates by reference information from your annual
report on Form 10-K for the year ended December 31, 2010. This filing does not contain
information in Part III that is required by Form 10-K. Prior to requesting acceleration of
effectiveness of the subject post-effective amendment, please amend your Form 10-K filing to
include Part III information or file the definitive proxy statement to incorporate this
information into your filing. |
ADVENTRX response: On April 28, 2011, we filed a definitive proxy statement pursuant to
Regulation 14(a) promulgated under the Securities Exchange Act of 1934, which includes the
Part III information that is required by Form 10-K. Such Part III information is
incorporated by reference into our annual report on Form 10-K for the year ended December
31, 2010.
Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, the Company hereby
requests acceleration of Post-Effective Amendment No. 3, so that it will become effective at 9:00
a.m., Eastern Daylight Time, on Friday, April 29, 2011, or as soon thereafter as reasonably
practicable, or at such later time as the Company may request by telephone to the Commission. The
Company hereby authorizes both Michael Kagnoff and Larry Nishnick of DLA Piper LLP (US), counsel
for the Company, to make such request on the Companys behalf.
The Company hereby acknowledges that: (i) should the Commission or the staff, acting pursuant
to delegated authority, declare the filing effective, it does not foreclose the Commission from
taking any action with respect to the filing; (ii) the action of the Commission or the staff,
acting pursuant to delegated authority, in declaring the filing effective, does not relieve the
Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing;
and (iii) the Company may not assert staff comments and the declaration of effectiveness as a
defense in any proceeding initiated by the Commission or any person under the federal securities
laws of the United States.
Mr. Jeffrey Riedler
Securities and Exchange Commission
April 28, 2011
Page 3
Securities and Exchange Commission
April 28, 2011
Page 3
Thank you for your assistance. If you should have any questions, please call Larry Nishnick
of DLA Piper LLP (US) at (858) 677-1414.
Very truly yours, ADVENTRX Pharmaceuticals, Inc. |
||||
By: | /s/ Patrick L. Keran | |||
Patrick L. Keran | ||||
President and Chief Operating Officer | ||||
cc: | John L. Krug, Senior Counsel, SEC Michael S. Kagnoff, DLA Piper LLP (US) Larry W. Nishnick, DLA Piper LLP (US) |